Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Laura Withorne Maloney

Nurse Practitioner, Family Sioux Falls, SD Nurse Practitioner

NPI 1255303707 CMS profile 10889523

4400 W 69Th St, Ste 500, Sioux Falls, SD 57108

Open in the dashboard

General payments

$1,737

56 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Withorne Maloney of Sioux Falls, SD is reported in the CMS Open Payments database as having received $1,737 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $527 26
2024 General $1,209 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Withorne Maloney
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Laura Withorne Maloney were reported at $527. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Laura Withorne Maloney Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $0 $141 $44–$430 $149
2023 $0 $154 $49–$476 $160
2024 $1,209 $165 $51–$504 $164
2025 $527 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. E.R. Squibb & Sons, L.L.C. $265 5 payments
  2. Supernus Pharmaceuticals, Inc. $244 3 payments
  3. Vanda Pharmaceuticals Inc. $226 3 payments
  4. Teva Pharmaceuticals USA, Inc. $147 2 payments
  5. Alkermes, Inc. $128 4 payments
  6. Tris Pharma Inc $124 1 payment
  7. Corium, Inc. $111 8 payments
  8. Neurocrine Biosciences, Inc. $94 6 payments
  9. Otsuka America Pharmaceutical, Inc. $78 5 payments
  10. Janssen Pharmaceuticals, Inc $75 4 payments
  11. Other $245 15 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $1,737 56 payments
Products named General payments · program years 2024–2025
  1. Qelbree $244 3 payments
  2. FANAPT $226 3 payments
  3. COBENFY Neuroscience $154 3 payments
  4. UZEDY $147 2 payments
  5. LYBALVI $128 4 payments
  6. Dyanavel XR $124 1 payment
  7. Quillivant $124 1 payment
  8. Quillichew ER $124 1 payment
  9. COBENFY Psychiatry/Psychology $111 2 payments
  10. Azstarys $111 8 payments
  11. Other $1,008 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,568

Median for Nurse Practitioner: 389

Drug cost

$132,199

Median for Nurse Practitioner: $21,885

Branded share of claims

23.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 22 $40,360
Vyvanse Lisdexamfetamine Dimesylate Brand 31 $11,536
Belsomra Suvorexant Brand 19 $10,656
Lurasidone Hcl Generic 18 $8,315
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 92 $5,983
Bupropion Xl Bupropion Hcl Brand 148 $5,750
Duloxetine Hcl Generic 205 $4,615
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 49 $4,160
Quetiapine Fumarate Generic 152 $4,072
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 124 $3,973

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$10,702

Medicare's payments for the services billed

Medicare patients

97

Average age 67

Services billed

192

76 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 59%
Arthritis 46%
Diabetes 28%
Osteoporosis 24%
Chronic kidney disease 22%
Ischemic heart disease 18%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $244
$244 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $226
$226 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $132
$132 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $111
$111 — —
Azstarys
  • Corium, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record